

## **Biotech/Pharma**

- **Investment Rational**

Vensica is a urology company that is developing the ViXe, a needle-free delivery device combined with botulinum toxin to treat overactive bladder, and other urological diseases. The company completed a pilot trial with promising results.

- **Business Strategy**

The OAB market needs new solutions, and specifically minimally invasive treatments for overactive bladder. Patients avoid invasive therapies, and physician are in need for simpler, financially rewarding solution. This is where Vensica comes in.

- **Core Technology**

Vensica unlocks the power of therapeutic ultrasound to deliver drugs to the bladder wall. This technology enables efficient delivery drugs, from small molecules to biologics, for different indications.

### **Product Profile/Pipeline**

Vensica's current focus is the development of Vibe with Xeomin (botulinum toxin A) for the treatment of OAB. The same product will be developed for other markets, such as Neurogenic bladder and painfull bladder syndrome. We also look at bladder cancer.

- **What's Next?**

The company just now completed \$19M financial round by leading investors, including Merz, a global pharmaco, Laborie, a large urology medical device company, IBF, and Lew Pell.

Vensica is preparing for a multicenter, double blind, 40 patients trial in Europe to in 2023 to demonstrate the safety and usability of the product.

## Questions for category: Service Provider

- **Main Service:**

Vensica is a urology company focusing on overactive bladder. Vensica is developing a drug-device combination product which includes the Vibe, a needle-free device to deliver drugs to the bladder wall, and Xeomin, an FDA/EU approved botulinum toxin A. Vensica holds the IP on Vibe, and has exclusivity on Xeomin for urology indications.

- **Key Strengths:**

Vensica has partnered with Merz Pharma, a global pharma leader. The partnership includes investment, and clinical and regulatory support, from Merz's in house expertise.

**Experience with Israeli Companies:**

NONE.

- **Key Markets:**

Vensica target and EU and the USA.